News & events

Search

10 Aug 2009

Ventavis (Iloprost) in pulmonary arterial hypertension receives US approval for increased 20 mcg/ml strength formulation

21 Jul 2009

Actelion announces Half Year financial results 2009

17 Jul 2009

Actelion's PGI2 receptor agonist demonstrates efficacy in pulmonary arterial hypertension patients - Morbidity-Mortality Phase III study to be initiated before year-end

06 Jul 2009

Tracleer (bosentan) receives EU approval for pediatric formulation - the first and only licensed pulmonary arterial hypertension therapy for children

12 Jun 2009

Management change at Actelion - Isaac Kobrin to take newly created position of Chief Medical Officer - Guy Braunstein to join as new Head of Clinical Development

08 May 2009

Actelion provides update on BUILD-3 study in Idiopathic Pulmonary Fibrosis - Study continues as recommended by the Independent Data and Safety Monitoring Board

24 Apr 2009

Bosentan (Tracleer®) receives positive CHMP opinion for pediatric formulation

24 Apr 2009

Annual General Meeting of Shareholders in Basel, Switzerland

21 Apr 2009

Actelion announces first quarter 2009 financial results

27 Mar 2009

Actelion proposes expansion of its Board of Directors

12 Mar 2009

Actelion Co-Founder Walter Fischli to focus on advancing scientific relationships between Actelion and leading academic institutes - Beat Steiner new Co-Head of Drug Discovery

02 Mar 2009

US Food and Drug Administration issues complete response letter regarding the Tracleer® supplemental New Drug Application - Completion and Approval of Risk Evaluation and Mitigation System (REMS) submission required for final FDA review for inclusion of less severe PAH patients in the product label

23 Feb 2009

Actelion announces acquisition of a new formulation of intravenous epoprostenol with improved thermal stability for the treatment of Pulmonary Arterial Hypertension

19 Feb 2009

Actelion announces Full Year 2008 financial results

29 Jan 2009

Zavesca® (miglustat) receives EU approval for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease

23 Jan 2009

Actelion to host Actelion Day on 19 February 2009

19 Dec 2008

Miglustat (Zavesca®) receives positive opinion from the European Committee for Medicinal Products for Human Use for an extension of indication for Niemann-Pick type C disease

13 Nov 2008

Actelion's first-in-class selective S1P1 receptor agonist to enter Phase II clinical development

21 Oct 2008

Actelion announces 9-months results for 2008

22 Sep 2008

Actelion included in the Swiss Market Index SMI
Page : 1 2 3 4 5 6 7 8 9 10

Top of page    Print pageSend this page to a friendBookmark with del.icio.usBookmark with diggBookmark with MISTER WONG

 

Corporate events

 21 Oct 2010 Q3 Results 2010
 17 Feb 2011 FY Results 2010
 19 Apr 2011 Q1 Results 2011

 
 

Related links

Actelion press releasesTracleer® congressesZavesca® congressesMedieninformationen